Contact Us

Smartphone-powered home urine test improves adherence to ACR testing in patients with type 1 diabetes

Case Study

Overview

Healthy.io’s ACR ‘Adherence as a Service’ enables people to test their urine at home using a test kit and accompanying app. The service improved adherence to ACR testing from 0% to 79% in patients with type 1 diabetes who had been offered the traditional model of care multiple times but did not attend, and consented to participate. This helped identify abnormal ACR in 17% of the patients that tested, that might not otherwise have been identified.

17%

of those tested had an abnormal or high abnormal result, indicating previously unknown albuminuria

94%

of patients contacted agreed to receive a test, out of which 79% completed an ACR test at home

97%

of patients agreed the service was easy to use

89%

preferred home testing to attending the clinic

The Challenge

An abnormal ACR test is an independent risk factor for both cardiovascular and chronic kidney disease (CKD). ACR testing is one of the worst performing of NICE recommended diabetes care processes, and is more frequently missed in people with type 1 diabetes than people with type 2.

The project was offered in collaboration with Diabetes Care for You, a service at Sussex Community NHS Trust, for patients living with type 1 diabetes across the Brighton and Hove and High Weald Lewes and Havens CCG areas.

ACR Adherence as a Service

onboarding
Patient onboarding

Patients were contacted by Healthy.io’s patient onboarding team, who provided information about the service, the importance of annual ACR testing, and supported patients to download the app.

home testing
Self-testing at home

Patients who consented to take part were sent a kit at home and a link to download an app that talks them through the process of home testing.

results
Results and follow-up

After completing the test, the results were available in SystmOne, the local electronic patient record system, for clinician review. Patient followup was initiated based on the ACR results.

Outcomes

 Increased adherence
Increased adherence

94% of patients contacted agreed to receive a test, out of which 79% completed one at home

Improved patient experience
Improved patient experience

97% agreed the service was easy to use. 89% preferred home testing to attending the clinic

Financial impact[1] CCGs
Financial impact1 CCGs

£533,572 in year 5 (£18,995 in year 1) Projected savings for Brighton and Hove and High Weald Lewes and Havens CCGs

Financial impact NHS
Financial impact NHS

£51,504,556 in year 5 (£1,833,571 in year 1) Projected savings for NHS England

The service enabled us to identify and prioritise follow-up care for people with early stage CKD that could have otherwise gone undetected.

David Lipscomb

Diabetes Clinical Lead

Sussex and East Surrey Health & Care Partnership

Make a difference for those at risk of CKD

Citations and Footnotes
  1. Projected savings are driven by early identification and intervention of CKD, reduced progression to ESRD and prevention of complications. Projection assumes the service was scaled to all patients with type 1 diabetes and no ACR recorded, with an 86% consent rate and 79% test completion rate. Based on York Health Economics Consortium (YHEC) financial modeling and data from the 2019 National Diabetes Audit.